Search Research

Durvalumab Plus Tremelimumab Alone or in Combination with Low-Dose or Hypofractionated Radiotherapy in Metastatic Non-Small-Cell Lung Cancer Refractory to Previous PD(L)-1 Therapy: an Open-Label, Multicentre, Randomised, Phase 2 Trial

Demographics (1)

SEX - Biological sex (phv00556889.v1.p1)

Other (10)

ANALYTE_TYPE - Analyte type (phv00556895.v1.p1)
BODY_SITE - Body site where sample was collected (phv00556893.v1.p1)
collection_event_name - Collection event name (phv00556894.v1.p1)
CONSENT - Registered consent groups (Data Use Limitations (DUL)) as determined by submitters' Institutional Review Boards (IRB) or equivalent body. (phv00556888.v1.p1)
IS_TUMOR - Tumor status (phv00556897.v1.p1)
sample_collection_procedure - Procedure for sample collection (phv00556896.v1.p1)
SAMPLE_ID - Sample ID (phv00556892.v1.p1)
SAMPLE_ID - Sample ID (phv00556891.v1.p1)
SUBJECT_ID - Subject ID (phv00556887.v1.p1)
SUBJECT_ID - Subject ID (phv00556890.v1.p1)